BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rühlemann M, Liwinski T, Heinsen FA, Bang C, Zenouzi R, Kummen M, Thingholm L, Tempel M, Lieb W, Karlsen T, Lohse A, Hov J, Denk G, Lammert F, Krawczyk M, Schramm C, Franke A. Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther 2019;50:580-9. [PMID: 31250469 DOI: 10.1111/apt.15375] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Hartmann P. Editorial: The Microbiome in Hepatobiliary and Intestinal Disease. Front Physiol 2022;13:893074. [DOI: 10.3389/fphys.2022.893074] [Reference Citation Analysis]
2 Di Giorgio A, Vergani D, Mieli-vergani G. Cutting edge issues in juvenile sclerosing cholangitis. Digestive and Liver Disease 2021. [DOI: 10.1016/j.dld.2021.06.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen H, Zhang F, Li R, Liu Y, Wang X, Zhang X, Xu C, Li Y, Guo Y, Yao Q. Berberine regulates fecal metabolites to ameliorate 5-fluorouracil induced intestinal mucositis through modulating gut microbiota. Biomed Pharmacother 2020;124:109829. [PMID: 31958765 DOI: 10.1016/j.biopha.2020.109829] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
4 Dean G, Hanauer S, Levitsky J. The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications. Hepatology. 2020;72:1127-1138. [PMID: 32394535 DOI: 10.1002/hep.31311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
5 Liwinski T, Heinemann M, Schramm C. The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts. Semin Immunopathol 2022. [PMID: 35536431 DOI: 10.1007/s00281-022-00936-6] [Reference Citation Analysis]
6 Appanna G, Kallis Y. An update on the management of cholestatic liver diseases. Clin Med (Lond) 2020;20:513-6. [PMID: 32934048 DOI: 10.7861/clinmed.2020-0697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hsu CL, Duan Y, Fouts DE, Schnabl B. Intestinal virome and therapeutic potential of bacteriophages in liver disease. J Hepatol 2021:S0168-8278(21)01997-8. [PMID: 34437908 DOI: 10.1016/j.jhep.2021.08.003] [Reference Citation Analysis]
8 Yan S, Yin XM. Gut microbiome in liver pathophysiology and cholestatic liver disease. Liver Res 2021;5:151-63. [PMID: 35355516 DOI: 10.1016/j.livres.2021.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Little R, Wine E, Kamath BM, Griffiths AM, Ricciuto A. Gut microbiome in primary sclerosing cholangitis: A review. World J Gastroenterol 2020; 26(21): 2768-2780 [PMID: 32550753 DOI: 10.3748/wjg.v26.i21.2768] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
10 Blesl A, Stadlbauer V. The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients 2021;13:1018. [PMID: 33801133 DOI: 10.3390/nu13031018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Rühlemann MC, Solovjeva MEL, Zenouzi R, Liwinski T, Kummen M, Lieb W, Hov JR, Schramm C, Franke A, Bang C. Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species. Gut 2020;69:1890-2. [PMID: 31653787 DOI: 10.1136/gutjnl-2019-320008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Li W, Zhang L, Xu Q, Yang W, Zhao J, Ren Y, Yu Z, Ma L. Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid. Nutrients 2022;14:1069. [DOI: 10.3390/nu14051069] [Reference Citation Analysis]
13 Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, Shao L. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol 2022;12:774335. [DOI: 10.3389/fcimb.2022.774335] [Reference Citation Analysis]
14 Jiang L, Stärkel P, Fan JG, Fouts DE, Bacher P, Schnabl B. The gut mycobiome: a novel player in chronic liver diseases. J Gastroenterol 2021;56:1-11. [PMID: 33151407 DOI: 10.1007/s00535-020-01740-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
15 Shah A, Macdonald GA, Morrison M, Holtmann G. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. Am J Gastroenterol 2020;115:814-22. [PMID: 32250997 DOI: 10.14309/ajg.0000000000000604] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
16 Liu Q, Li B, Li Y, Wei Y, Huang B, Liang J, You Z, Li Y, Qian Q, Wang R, Zhang J, Chen R, Lyu Z, Chen Y, Shi M, Xiao X, Wang Q, Miao Q, Fang JY, Gershwin ME, Lian M, Ma X, Tang R. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut 2021:gutjnl-2020-323565. [PMID: 34035120 DOI: 10.1136/gutjnl-2020-323565] [Reference Citation Analysis]
17 Beheshti-Maal A, Tamimi A, Iravani S, Memarnejadian A, Sorouri M, Aghdaei HA, Zali MR, Hossein Khannazer N, Vosough M. PSC associated inflammatory bowel disease: A distinct entity. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35078376 DOI: 10.1080/17474124.2022.2031979] [Reference Citation Analysis]
18 Rühlemann M, Liwinski T, Heinsen FA, Bang C, Zenouzi R, Kummen M, Thingholm L, Tempel M, Lieb W, Karlsen T, Lohse A, Hov J, Denk G, Lammert F, Krawczyk M, Schramm C, Franke A. Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther 2019;50:580-9. [PMID: 31250469 DOI: 10.1111/apt.15375] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
19 Quraishi MN, Shaheen WA. Editorial: gut microbial profile associated with primary sclerosing cholangitis-what is new and how do we progress from here? Aliment Pharmacol Ther 2019;50:605-6. [DOI: 10.1111/apt.15424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Deeb M, Karlsen TH, Hirschfield GM. The 6 C's of primary sclerosing cholangitis. J Hepatol 2020;73:1255-6. [PMID: 32649970 DOI: 10.1016/j.jhep.2020.06.033] [Reference Citation Analysis]
21 Rühlemann M, Franke A. Editorial: gut microbial profile associated with primary sclerosing cholangitis-what is new and how do we progress from here? Authors' reply. Aliment Pharmacol Ther 2019;50:606-7. [PMID: 31414547 DOI: 10.1111/apt.15434] [Reference Citation Analysis]
22 Chen J, Vitetta L. Letter to the Editor: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment? Hepatology 2020;72:1497-8. [PMID: 32329075 DOI: 10.1002/hep.31269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol 2020;55:588-614. [PMID: 32222826 DOI: 10.1007/s00535-020-01681-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
24 Floreani A, De Martin S, Ikeura T, Okazaki K, Gershwin ME. Gut microbial profiling as a therapeutic and diagnostic target for managing primary biliary cholangitis. Expert Opinion on Orphan Drugs 2020;8:507-14. [DOI: 10.1080/21678707.2020.1865917] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Özdirik B, Müller T, Wree A, Tacke F, Sigal M. The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. Int J Mol Sci 2021;22:6975. [PMID: 34203536 DOI: 10.3390/ijms22136975] [Reference Citation Analysis]
26 Czaja AJ. Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease. World J Gastroenterol 2021; 27(25): 3705-3733 [PMID: 34321839 DOI: 10.3748/wjg.v27.i25.3705] [Reference Citation Analysis]
27 Visseren T, Fuhler GM, Erler NS, Nossent YRA, Metselaar HJ, IJzermans JNM, Darwish Murad S, Peppelenbosch MP. Recurrence of primary sclerosing cholangitis after liver transplantation is associated with specific changes in the gut microbiome pretransplant - a pilot study. Transpl Int 2020;33:1424-36. [PMID: 33617049 DOI: 10.1111/tri.13692] [Reference Citation Analysis]
28 Zheng Y, Ran Y, Zhang H, Wang B, Zhou L. The Microbiome in Autoimmune Liver Diseases: Metagenomic and Metabolomic Changes. Front Physiol 2021;12:715852. [PMID: 34690796 DOI: 10.3389/fphys.2021.715852] [Reference Citation Analysis]
29 Thompson MD, Hinrichs H, Faerber A, Tarr PI, Davidson NO. MATERNAL OBESOGENIC DIET ENHANCES CHOLESTATIC LIVER DISEASE IN OFFSPRING. J Lipid Res 2022;:100205. [PMID: 35341737 DOI: 10.1016/j.jlr.2022.100205] [Reference Citation Analysis]
30 Denoth L, Juillerat P, Kremer AE, Rogler G, Scharl M, Yilmaz B, Bluemel S, On Behalf Of The Swiss Ibd Cohort Study. Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis. Microorganisms 2021;9:1752. [PMID: 34442830 DOI: 10.3390/microorganisms9081752] [Reference Citation Analysis]
31 Liwinski T, Casar C, Ruehlemann MC, Bang C, Sebode M, Hohenester S, Denk G, Lieb W, Lohse AW, Franke A, Schramm C. A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis. Aliment Pharmacol Ther 2020;51:1417-28. [DOI: 10.1111/apt.15754] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
32 Abbas N, Quraishi MN, Trivedi P. Emerging drugs for the treatment of primary sclerosing cholangitis. Curr Opin Pharmacol 2021;62:23-35. [PMID: 34894541 DOI: 10.1016/j.coph.2021.11.003] [Reference Citation Analysis]
33 Attauabi M, Wewer MD, Bendtsen F, Seidelin JB, Burisch J. Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis. Inflamm Bowel Dis 2022:izac003. [PMID: 35134921 DOI: 10.1093/ibd/izac003] [Reference Citation Analysis]
34 Hu L, Jin L, Xia D, Zhang Q, Ma L, Zheng H, Xu T, Chang S, Li X, Xun Z, Xu Y, Zhang C, Chen F, Wang S. Nitrate ameliorates dextran sodium sulfate-induced colitis by regulating the homeostasis of the intestinal microbiota. Free Radic Biol Med 2020;152:609-21. [PMID: 31811920 DOI: 10.1016/j.freeradbiomed.2019.12.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
35 Kummen M, Thingholm LB, Rühlemann MC, Holm K, Hansen SH, Moitinho-Silva L, Liwinski T, Zenouzi R, Storm-Larsen C, Midttun Ø, McCann A, Ueland PM, Høivik ML, Vesterhus M, Trøseid M, Laudes M, Lieb W, Karlsen TH, Bang C, Schramm C, Franke A, Hov JR. Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. Gastroenterology 2021;160:1784-1798.e0. [PMID: 33387530 DOI: 10.1053/j.gastro.2020.12.058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]